PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma

-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion

-Tremelimumab will be administered first

-Integrated electroporation device

-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.

-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1